HgCapital puts another £8.1m into Evaluate
HgCapital Trust announced an additional investment into pharmaceutical intelligence and predictive analytics company Evaluate on Monday, with the terms of the transaction not disclosed.
The FTSE 250 company said the transaction would result in it investing about £8.1m in Evaluate, alongside other institutional clients of Hg.
It said the transaction represented an uplift on its current investment in Evaluate of £3.1m, 40%, or 1p per share over the carrying value of £7.7m in the net asset value of HgCapital Trust as at 31 March.
“HgCapital Trust’s liquid resources available for future deployment are estimated to be £126.8m, [or] 13% of the 31 March pro-forma net asset value of £968m,” the board said in its statement.
“The investment will reduce HgCapital Trust’s outstanding commitments to invest in Hg transactions to approximately £908m.”
At 0906 BST, shares in HgCapital Trust were down 0.042% at 246.6p.